Skip to main content

Advertisement

ADVERTISEMENT

Volume 18 - Issue 1 - January, 2006

Feature

Case Report
08/01/2008
Abdul Rashid, MD, Jorge Saucedo, MD, Thomas A. Hennebry, MD
Abdul Rashid, MD, Jorge Saucedo, MD, ...
Case Report. A 57-year-old woman underwent orthotopic cardiac transplant in 1997 secondary to nonischemic cardiomyopathy. Her symptoms of heart failure started in 1993 after a week of flu-like illness. A year later, she was diagnosed with...
Case Report. A 57-year-old woman underwent orthotopic cardiac transplant in 1997 secondary to nonischemic cardiomyopathy. Her symptoms of heart failure started in 1993 after a week of flu-like illness. A year later, she was diagnosed with...
Case Report. A 57-year-old woman...
08/01/2008
Journal of Invasive Cardiology
Case Report
08/01/2008
Josef Veselka, MD, PhD, FESC, FSCAI and David Zem√°nek, MD
Josef Veselka, MD, PhD, FESC, FSCAI a...
Aneurysms of the ascending aorta are not uncommon in the catheterization laboratory. When encountered, they lead to problems catheterizing the left coronary artery in particular. We typically use catheters with a large bend in these cases...
Aneurysms of the ascending aorta are not uncommon in the catheterization laboratory. When encountered, they lead to problems catheterizing the left coronary artery in particular. We typically use catheters with a large bend in these cases...
Aneurysms of the ascending aorta...
08/01/2008
Journal of Invasive Cardiology
Case Report
08/01/2008
Alan Zajarias, MD, Srihari Thanigaraj, MD, Megumi Taniuchi, MD, PhD
Alan Zajarias, MD, Srihari Thanigaraj...
Non-penetrating thoracic trauma has been associated with multiple structural and electrical cardiac injuries and complications with a mortality rate of up to 15%.1 The mechanisms for non-penetrating cardiac injury include: direct trauma,...
Non-penetrating thoracic trauma has been associated with multiple structural and electrical cardiac injuries and complications with a mortality rate of up to 15%.1 The mechanisms for non-penetrating cardiac injury include: direct trauma,...
Non-penetrating thoracic trauma...
08/01/2008
Journal of Invasive Cardiology
Case Report
08/01/2008
S. Anandaraja, MD, DM, Nitish Naik, MD, Kewal Talwar, MD
S. Anandaraja, MD, DM, Nitish Naik, M...
Percutaneous coronary interventions (PCI) are uncommon causes of coronary artery aneurysms (CAA). The incidence of CAA after percutaneous transluminal coronary angioplasty (PTCA) ranges from 3.9–5%,1,2,5–7 and after directional coronary...
Percutaneous coronary interventions (PCI) are uncommon causes of coronary artery aneurysms (CAA). The incidence of CAA after percutaneous transluminal coronary angioplasty (PTCA) ranges from 3.9–5%,1,2,5–7 and after directional coronary...
Percutaneous coronary...
08/01/2008
Journal of Invasive Cardiology
IAGS (International Andreas Gruentzig Society) Proceedings
08/01/2008
Speaker: Douglas Cavaye, MD and Michael Marin, MD Moderators: Eberhard Zeitler, MD and Klemens Barth, MD Panelists: Michael Lawrence-Brown, MD, Ernst Schneider, MD, Wolfgang Ritter, MD, Andrew Cragg, MD
Speaker: Douglas Cavaye, MD and Micha...
Wolfgang Ritter: We know that all devices have problems; for example, the VanGuard or the AneuRx® (Medtonic, Inc., Sunnyvale, California) can incur some disintegration 4 to 5 years postimplantation. With the Zenith device, the problem of late...
Wolfgang Ritter: We know that all devices have problems; for example, the VanGuard or the AneuRx® (Medtonic, Inc., Sunnyvale, California) can incur some disintegration 4 to 5 years postimplantation. With the Zenith device, the problem of late...
Wolfgang Ritter: We know that...
08/01/2008
Journal of Invasive Cardiology
IAGS (International Andreas Gruentzig Society) Proceedings
08/01/2008
Moderator: Mike Cowley Panelists: Scott Byrd and Philip Reid (Eli Lilly and Company); Renato DeRita (Centocor); John Spencer (Genentech)
Moderator: Mike Cowley Panelists: Sco...
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly &...
08/01/2008
Journal of Invasive Cardiology

Column

Editorial Message
08/01/2008
Richard E. Shaw, PhD, FACC, FACA Editor-in-Chief
Richard E. Shaw, PhD, FACC, FACA Edit...
Dear Readers, This issue of the Journal of Invasive Cardiology commences our 18th year of publication. There has been incredible growth in the field of invasive cardiology during 2005. Many of these growth areas have challenged the...
Dear Readers, This issue of the Journal of Invasive Cardiology commences our 18th year of publication. There has been incredible growth in the field of invasive cardiology during 2005. Many of these growth areas have challenged the...
Dear Readers, This issue of the...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
Raul Moreno, MD, Cesar Conde, MD, Maria-Jose Perez-Vizcayno, MD, Sergio Villarreal, MD, Rosana Hernandez-Antolin, MD, Fernando Alfonso, MD, Camino Bañuelos, MD, Dominick J. Angiolillo, MD, Javier Escaned, MD, Antonio Fernandez-Ortiz, MD, Carlos Macaya, MD
Raul Moreno, MD, Cesar Conde, MD, Mar...
Primary percutaneous coronary intervention (PCI) is the best reperfusion strategy in patients with ST-elevation acute myocardial infarction (AMI).1 This is mainly because it achieves a very high rate of successful recanalization of the...
Primary percutaneous coronary intervention (PCI) is the best reperfusion strategy in patients with ST-elevation acute myocardial infarction (AMI).1 This is mainly because it achieves a very high rate of successful recanalization of the...
Primary percutaneous coronary...
08/01/2008
Journal of Invasive Cardiology
08/01/2008
Carlos A.M. Gottschall, MD, PhD, Alexandre S. Quadros, MD, PhD, Rogerio Sarmento-Leite, MD, PhD
Carlos A.M. Gottschall, MD, PhD, Alex...
Drug-eluting stents (DES) significantly decrease the need for a new target vessel revascularization (TVR) after coronary intervention,1–4 but its widespread use is still limited by cost issues.5,6 DES are currently used in more than 70% of...
Drug-eluting stents (DES) significantly decrease the need for a new target vessel revascularization (TVR) after coronary intervention,1–4 but its widespread use is still limited by cost issues.5,6 DES are currently used in more than 70% of...
Drug-eluting stents (DES)...
08/01/2008
Journal of Invasive Cardiology

Insights

Commentary
08/01/2008
Frederick G.P. Welt, MD and Douglas W. Losordo, MD
Frederick G.P. Welt, MD and Douglas W...
Nearly two years after the widespread introduction of drug-eluting stents (DES) on the U.S. market, it is perhaps time to step back and evaluate the impact of this revolutionary technology on the practice of cardiology. Financial modeling has...
Nearly two years after the widespread introduction of drug-eluting stents (DES) on the U.S. market, it is perhaps time to step back and evaluate the impact of this revolutionary technology on the practice of cardiology. Financial modeling has...
Nearly two years after the...
08/01/2008
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement